相关实验视频
Updated: Jan 14, 2026

08:58
Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis
Published on: March 11, 2017
16.8K
对于怀孕年龄来说,出生小的儿童体脂肪正常,但hs-CRP和肝细胞脂质含量升高
Leena Hintikka1,2, Jarmo Jääskeläinen1,2, Riina Palonen2,3
1Department of Pediatrics, Kuopio University Hospital, Kuopio, Finland.
Pediatric research
|October 16, 2025
概括
出生小于孕期 (SGA) 的孩子有更高的肝脂肪和炎症标志物. 这些发现表明,SGA儿童肝脏甘油三和hs-CRP的升高可能是未来心脏代谢风险的信号.
科学领域:
- 儿科内分泌学 儿科内分泌学
- 代谢健康 代谢健康
- 医疗成像医学成像
背景情况:
- 对于妊娠年龄 (SGA) 的小出生与成人心脏代谢疾病风险的增加有关.
- 在青春期前的儿童中,肝细胞脂质 (HCL) 度受出生大小的影响.
研究的目的:
- 研究出生大小对前青春期儿童肝细胞脂质 (HCL) 度的影响.
- 为了确定出生大小,肝脏脂肪和代谢/炎症标志物之间的关联.
主要方法:
- 195名青春期前儿童 (4.4-9.7岁) 被分类为SGA,适合妊娠年龄 (AGA) 或适合妊娠年龄的大 (LGA).
- 评估包括体脂肪的双能量X射线吸收度 (DXA),肝脂肪的MRI/MR光谱 (MRS),人体测量和生物化学标记.
- 质子MR光谱学 (MRS) 量化了HCL度.
主要成果:
- 在SGA儿童中,MRS检测到的HCL度显著更高 (p=0.02).
- 与AGA和LGA组相比,在SGA儿童中观察到高灵敏度C反应蛋白 (hs-CRP) 水平的升高 (p=0.01,p=0.002).
- HCL度与hs-CRP值相关 (R=0.51,p=0.03),独立于传统的人类测量标记.
结论:
- 在青春期前的儿童中,SGA状态与MRS可检测的高HCL和hs-CRP有关.
- 在SGA儿童中肝脏甘油三和hs-CRP的升高可能是代谢变化的早期指标.
- MRS可以识别有潜在代谢后果的风险儿童.
相关概念视频
Pathophysiology of Diabetes
3.1K
Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
3.1K
Pharmacokinetics in Pediatric Patients: Drug Metabolism
191
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
191
Obesity
1.1K
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.1K
Nature and Nurture
22.2K
Many human characteristics, like height, are shaped by both nature—in other words, by our genes—and by nurture, or our environment. For example, chronic stress during childhood inhibits the production of growth hormones and consequently reduces bone growth and height. Scientists estimate that 70-90% of variation in height is due to genetic differences among individuals, and 10-30% of variation in height is due to differences in the environments that individuals experience,...
22.2K
Pharmacokinetics in Pediatric Patients: Drug Distribution
251
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
251

